USA - NASDAQ:GPCR - US86366E1064 - ADR
Overall GPCR gets a fundamental rating of 3 out of 10. We evaluated GPCR against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for GPCR as it has an excellent financial health rating, but there are worries on the profitability. GPCR has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.92% | ||
| ROE | -23.18% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 22.51 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.48 | ||
| Quick Ratio | 20.48 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
32.22
+2.65 (+8.96%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.4 | ||
| P/tB | 2.4 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.92% | ||
| ROE | -23.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 113.06% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 20.48 | ||
| Quick Ratio | 20.48 | ||
| Altman-Z | 22.51 | 
ChartMill assigns a fundamental rating of 3 / 10 to GPCR.
ChartMill assigns a valuation rating of 0 / 10 to STRUCTURE THERAPEUTICS INC (GPCR). This can be considered as Overvalued.
STRUCTURE THERAPEUTICS INC (GPCR) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of STRUCTURE THERAPEUTICS INC (GPCR) is expected to grow by 31.48% in the next year.